Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

Sho Suzuki, Mitsuru Esaki, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda

ORCID number: Sho Suzuki (0000-0003-4831-1409); Mitsuru Esaki (0000-0001-7353-2153); Chika Kusano (0000-0002-3789-4787); Hisatomo Ikehara (0000-0001-9239-7495); Takuji Gotoda (0000-0001-6904-6777).

Author contributions: All authors contributed equally to the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and approval of the final version.

Conflict-of-interest statement: Gotoda T received honorarium from AstraZeneca K.K., Daiichi Sankyo Company Limited, EA Pharma Co., Ltd., and Takeda Pharmaceutical Company Limited.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Abstract

Helicobacter pylori (H. pylori) antimicrobial resistance is an urgent, global issue. In 2017, the World Health Organization designated clarithromycin-resistant H. pylori as a high priority bacterium for antibiotic research and development. In addition to clarithromycin, resistance to metronidazole and fluoroquinolones has also increased worldwide. Recent international guidelines for management of H. pylori infection recommend bismuth or non-bismuth quadruple therapy for 14 d as a first-line treatment for H. pylori in areas of high clarithromycin and/or metronidazole resistance. Although these treatment regimens provide acceptable H. pylori eradication rates, the regimens used should not contribute to future resistance of H. pylori to antimicrobials. Moreover, these regimens can promote resistance, due to prolonged therapy with multiple antibiotics. A new strategy that can eradicate H. pylori as well as reduce the antibiotics used is required to prevent future antimicrobial resistance in H. pylori. Dual-therapy with vonoprazan and amoxicillin could be a breakthrough for H. pylori eradication in an era of growing antimicrobial resistance. This regimen may provide a satisfactory eradication rate of H. pylori and also minimize antimicrobial resistance due to single antibiotic use and the strong inhibitory effect of vonoprazan on gastric acid secretion.

Key words: Helicobacter pylori; Antibiotic resistance; Antimicrobial resistance; Dual therapy; Vonoprazan

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The increasing antimicrobial resistance of Helicobacter pylori (H. pylori) is an urgent, global issue. Although current H. pylori treatment regimens provide acceptable eradication rates, these regimens could also be improved to optimize antibiotic usage and...
prevent antimicrobial resistance because these regimens use multiple antibiotic agents and have a long treatment duration. Dual therapy consisting of vonoprazan and amoxicillin may be an alternative treatment regimen for *H. pylori* eradication in an era of growing antimicrobial resistance and may provide sufficient *H. pylori* eradication rates and may help prevent future antimicrobial resistance of *H. pylori*.

Citation: Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of *Helicobacter pylori* treatment: How do we manage antimicrobial resistance? *World J Gastroenterol* 2019; 25(16): 1907-1912

URL: https://www.wjgnet.com/1007-9327/full/v25/i16/1907.htm

DOI: https://dx.doi.org/10.3748/wjg.v25.i16.1907

---

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*) infection, one of the most common bacterial infections, affects approximately 50% of the world’s population[1]. *H. pylori* infection is a major cause of gastritis, gastric and duodenal ulcers, mucosal associated lymphoid tissue, and gastric cancer[3]. *H. pylori* eradication treatment has been proven to improve gastric inflammation, promote ulcer healing, and reduce the incidence of gastric cancer[4-6]. Furthermore, a "test-and-treat" approach is advocated for detecting and eradicating *H. pylori* in patients with dyspeptic symptoms but low gastric cancer risk[5].

*H. pylori* eradication treatment is becoming more challenging due to increasing antimicrobial resistance. Previously, a 7-d standard triple therapy consisting of a proton pump inhibitor (PPI), amoxicillin (AMPC), and clarithromycin (CAM) was recommended for eradicating *H. pylori*[6]. However, there has been a significant reduction in the eradication rate achieved with this regimen due to the increase in antimicrobial resistance of *H. pylori*. Resistance of *H. pylori* has reached alarming levels worldwide, which greatly affects the efficacy of treatment. The World Health Organization (WHO) recently published its first ever list of antimicrobial resistant “priority pathogens,” which is a catalogue of 12 families of bacteria posing the greatest threat to human health. They indicated three priority statuses-critical, high, and medium-with CAM-resistant *H. pylori* being categorized as a high priority bacterium in the same tier as vancomycin-resistant *Enterococcus faecium* and methicillin-resistant *Staphylococcus aureus*. Furthermore, resistance to metronidazole (MNZ) and fluoroquinolones, which are mainly used as rescue therapies[7], has also increased more recently to over 15% in many regions of the world[8,9]. Thus, the mere avoidance of CAM in *H. pylori* eradication treatment is not enough to prevent and decrease antimicrobial resistance of *H. pylori*. Actually, a recent study of the influence of a government-introduced, restrictive antibiotic policy on the rates of resistance of *H. pylori* in Taiwan indicated an increase in levofloxacin resistance since the restriction of macrolides[10].

**RECENT STANDARD *H. PYLORI* THERAPIES AND THE CONCERN FOR ANTMICROBIAL RESISTANCE**

Treatment regimens are expected to overcome the increasing prevalence of resistant strains of *H. pylori* and achieve a > 90% eradication rate. The eradication rates for first-line *H. pylori* treatment regimens published in meta-analysis and in a study of eradication rates of vonoprazan-based dual therapy are shown in Table 1. Recently, bismuth-containing quadruple therapy (BQT) or non-bismuth concomitant quadruple therapy (CQT) has been recommended by international guidelines as a first-line treatment for *H. pylori* in areas of high CAM and/or MNZ resistance[2,11,12]. Both BQT and CQT contain PPI and two to three kinds of antibiotic agents including AMPC, CAM, MNZ, nitroimidazole, and tetracycline with longer treatment durations of 10-14 d. It is reported that acceptable eradication rates of > 90% have been obtained by both regimens. Although BQT and CQT provide acceptable *H. pylori* eradication rates, they have many limitations, such as a complicated protocol, high cost, adverse side effects, and poor patient compliance due to multiple drug combinations[13]. Furthermore, these regimens must not contribute to antimicrobial resistance of *H. pylori*; moreover,
they may promote future resistance because of the use of multiple antibiotics for a long duration. The alarming global rates of *H. pylori* resistance in treatment-naïve patients can be correlated with the increasing and uncontrolled use of antibiotics that are commonly used in *H. pylori* empirical therapy and in therapy for other common infections in the general population[14]. Increased antibiotic usage worldwide has led to antimicrobial resistance among many bacteria, including *H. pylori*, resulting in falling success rates of *H. pylori* eradication treatment. These regimens could also be improved to optimize antibiotic usage to prevent antimicrobial resistance.

WHO launched the Global Action Plan on Antimicrobial Resistance to ensure, for as long as possible, the continuity of the ability to treat and prevent infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them. Five objectives are listed in this document and the fourth objective is “to optimize the use of antimicrobial medicines in human and animal health.” They state that “extent of reduction in global human consumption of antibiotics, the consumption of antibiotics used in food production, and the use of medical and veterinary antimicrobial agents for applications other than human and animal health” are a potential measure of effectiveness for optimizing the use of antimicrobial medicines in human and animal health. Thus, the increase in resistance to *H. pylori* and the existence of multi-resistance to various families of antibiotics must be addressed by the appropriate use of antibiotics in *H. pylori* treatment. Antimicrobial susceptibility testing is the best way to optimize and reduce antibiotics for *H. pylori* eradication treatment as well as treating other common infections. Antimicrobial susceptibility testing is recommended to enable tailoring of the eradication therapy presented in the international guidelines[15], to ensure successful eradication[16,17]. However, antimicrobial susceptibility testing is not a routine clinical practice due to the invasiveness of the endoscopy procedure, time consuming nature, the availability of laboratory culture facilities, and cost considerations[17]; non-invasive methods are being developed[18].

**PROSPECTS OF NEW STRATEGIES FOR ENSURING ERADICATION OF *H. PYLORI* AND PREVENTION OF ANTIMICROBIAL RESISTANCE**

A new strategy that could provide sufficient eradication rates as well as decrease the amount of antibiotics is essential for the prevention of future antimicrobial resistance of *H. pylori*. Dual therapy with AMPC and PPI could be a possible solution because this regimen is a single-antibiotic therapy, and it is well known that *H. pylori* is hardly resistant to AMPC. Currently, the resistance rates of *H. pylori* to AMPC remain low (0%-5%)[19-21]. A dual therapy comprising a PPI and AMPC was first introduced in the 1990s as a first-line regimen for *H. pylori* infection[22]. As dual therapy of PPI and AMPC administered at standard doses did not achieve satisfactory treatment outcomes[22,23], it was subsequently used as a salvage treatment. Recently, Yang et al[24] reported that a high-dose dual therapy consisting of AMPC and rabeprazole achieved an eradication rate of 95.3% in first-line therapy, and 89.3% in rescue therapy. However, this method needed a high frequency and a high dose of AMPC and PPI for a longer duration (e.g., rabeprazole 20 mg and amoxicillin 750 mg 4 times/d for 14 d) to attain an acceptable eradication rate of >90%, which led to high cost, adverse side effects, and poor patient compliance.

One interesting possibility is to substitute conventional PPIs with vonoprazan for use in dual therapies. Vonoprazan-based dual therapy could be an alternative treatment regimen for *H. pylori* eradication, which could provide sufficient eradication rates of *H. pylori* and minimize antimicrobial resistance. The key to a successful dual therapy regimen is a PPI-generated neutral environment suitable for bacterial growth; this causes dormant *H. pylori* to enter a replicative state and makes *H. pylori* sensitive to AMPC. Vonoprazan is a novel potassium competitive acid blocker that has a strong and long-lasting effect on inhibition of acid secretion[25,26]. In addition, the pharmacokinetic features of vonoprazan are not affected by CYP2C19 polymorphisms[27,28]. It is reported that seven days of standard triple therapy containing vonoprazan provided approximately 90% eradication rate attributable to effective gastric acid inhibition and the maintenance of a high gastric pH, and had a high safety profile irrespective of age[28,29]. To the best of our knowledge, there is only one study on vonoprazan and AMPC dual therapy; this study showed that a regimen consisting of vonoprazan 20 mg twice per day and AMPC 500 mg three times/d for seven days provided sufficient eradication rates of 93.8% of *H. pylori* infection[30]. This seven-day, vonoprazan-based dual therapy may have additional advantages in terms of treatment compliance and medical costs as fewer agents are used and the duration...
Table 1  Treatment regimens for first-line *Helicobacter pylori* therapies and its successful eradication rates

| Regimens                        | PPI                        | Antibiotics                          | Treatment duration | Eradication rates |
|---------------------------------|----------------------------|--------------------------------------|--------------------|-------------------|
| Bismuth quadruple therapy       | Esomeprazole 20-40 mg bid; | TC 125 mg *qid*, MNZ 125 mg *qid*    | 10 d               | 90%[50]           |
|                                 | Omeprazole 20-40 mg bid    |                                      |                    |                   |
| Concomitant quadruple therapy   | Esomeprazole 20-40 mg bid; | AMPC 750 mg-1 g bid; CAM 200-500 mg bid; MNZ or TNZ 250-500 mg bid  | 5-14 d             | 83%[56]           |
|                                 | Lansoprazole 30 mg bid;    |                                      |                    |                   |
|                                 | Omeprazole 20-40 mg bid;   |                                      |                    |                   |
|                                 | Pantoprazole 40 mg bid;     |                                      |                    |                   |
|                                 | Rabeprazole 10-20 mg bid   |                                      |                    |                   |
| Standard triple therapy         | Esomeprazole 40 mg bid;    | AMPC 500 mg-1 g bid; CAM 200-500 mg bid | 7 d[37]; 14 d[38] | 73%[37]; 81%[38] |
|                                 | Lansoprazole 30 mg bid;    |                                      |                    |                   |
|                                 | Pantoprazole 40 mg bid;     |                                      |                    |                   |
|                                 | Rabeprazole 10-20 mg bid   |                                      |                    |                   |
| High dose dual therapy          | Esomeprazole 20 mg *qid*;  | AMPC 750 mg *qid*                     | 14 d               | 86%[39]           |
|                                 | Omeprazole 40 mg *qid*;    |                                      |                    |                   |
|                                 | Rabeprazole 10-20 mg *qid* |                                      |                    |                   |
| Vonoprazan based triple therapy | vonoprazan 20 mg *bid*;    | AMPC 750 mg *bid*; CAM 200-400 mg *bid* | 7 d               | 88%[31]           |
| Vonoprazan based dual therapy   | vonoprazan 20 mg *bid*;     | AMPC 500 mg *tid*                     | 7 d               | 94%[32]           |

PPI: Proton pump inhibitor; TC: Tetracycline; MNZ: Metronidazole; AMPC: Amoxicillin; CAM: Clarithromycin; TNZ: Tinidazole.

of the therapy is shorter than that of other recent standard treatment regimens (such as BQT, CQT, and sequential therapies). Vonoprazan-based dual therapy may be a recent breakthrough that could ensure a satisfactory eradication rate with the use of minimum antibiotic agents and a short treatment duration. Furthermore, reducing antibiotics may prevent changes and dysbiosis in gut microbiota composition, which are caused by antibiotics used in *H. pylori* eradication therapy[33]. Although vonoprazan-based dual therapy potentially has these advantages, it also has several limitations for implementation in clinical setting. First, vonoprazan is available in a few countries. Vonoprazan was developed and launched in Japan in 2015. However, it is now available in several Asian countries including Philippine, Singapore, and Thailand, and has been approved in other regions, including South America (countries such as Argentina and Peru). Thus, vonoprazan may become available and can be used for *H. pylori* eradication therapy worldwide in the near future. Second, this regimen cannot be used in patients with penicillin allergy and thus antimicrobial susceptibility testing should be performed in these patients to optimize *H. pylori* eradication therapy. Although the conventional antimicrobial susceptibility testing is invasive due to the need of endoscopy and biopsy as mentioned above, a non-invasive molecular test using fecal sample has also been recently developed[34]. This method involves the isolation of *H. pylori* DNA from stool and detection of point mutations conferring antimicrobial resistance by polymerase chain reaction. This method should be considered for testing antimicrobial susceptibility in patients with penicillin allergy before *H. pylori* eradication therapy. Finally, there are few data and studies regarding this regimen. Further studies should be conducted to prove its efficacy and safety profile.

**CONCLUSION**

In this review, we outline the urgent, global issue of *H. pylori* antimicrobial resistance and propose our prospects of approach for the issue. *H. pylori* treatment is becoming more challenging because of the increasing antimicrobial resistance to not only CAM but also to MNZ and fluoroquinolones. Thus, there is a need to develop new *H. pylori* eradication therapies that provide an acceptable eradication rate, better safety and tolerability profile, and good patient compliance, while preventing the increase in *H. pylori* antimicrobial resistance. One interesting possibility is the use of vonoprazan in dual therapy with AMPC, which has been shown to have over a 90% eradication rate. Large scale, randomized control trials should be conducted to verify and establish this finding in the future.

**REFERENCES**
[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate

Hori Y

Gastroenterol Hepatol 2015; 362: 1597-1604

Doerrakers E, Lagergren J, Engstrand L, Brusselmann S. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut 2018; 67: 2092-2096

McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-1604

Doerrakers E, Lagergren J, Engstrand L, Brusselmann S. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut 2018; 67: 2092-2096

Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon A, Bazzoli F, Gasbarrini A, Atherton I, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florencen Consensus Report. Gut 2017; 66: 6-30

Malfertheiner P, Megraud F, O'Morain CA, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Yaksh N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781

Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24: 4548-4553

Thung T, Araman H, Vavinikaaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-533

Savoldi A, Carrara E, Graham DY, Conti M, Taccconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382.e17

Lion JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee YJ, Wu YJ, Luo JC, Lion TC, Chang WH, Tseng CH, Wu CY, Yang TH, Chang CC, Wang HP, Sheu BS, Lin JT, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS One 2015; 10: e0124199

Choi LI, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. Helicobacter pylori therapy for the prevention of Metachronous Gastric Cancer. N Engl J Med 2018; 378: 1085-1095

Chey WD, Leontiads GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112: 212-239

Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Rendel C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151: 51-69.e14

Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015; 64: 1715-1720

Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384

Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizazano J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World Gastroenterol 2017; 23: 3367-3373

Arslan N, Yilmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23: 2854-2869

Abadi ATB. Resistance to clarithromycin and gastointestinalist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. Gut 2017; 66: 6-30

Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, Palmer SC, Barone M, Principi M, Strippoli GF, Di Leo A, Ierardi E. New fecal test for non-invasive Helicobacter pylori infection. Aliment Pharmacol Ther 2016; 43: 272-273

Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013; 18: 274-279

Zhang VX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol 2015; 21: 2786-2792

Bayerdörffer E, Mielke S, Mannes GA, Sommer A, Höchter W, Weingart J, Heldwein W, Klann H, Bayerdörffer E. Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 301-304

Wong BC, Xiao SD, Hu FL, Quan SC, Huang NX, Li YY, Hu PJ, Mao L, Lin CC, Chang WH, Capio RE, Perez YJ, Fock KM, Kachintorn U, Phromthep K, Kullavanijaya P, Ho J, Lam SK. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther 2000; 14: 217-224

Yang JG, Lin CJ, Wang HL, Chen JD, Kao YJ, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015; 13: 895-905.e5

Hori Y, Imamiishi A, Matsukawa J, Tsukimi Y, Nishida H, Arakawa Y, Hirakae K, Kajino M, Inatomi N. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-yl)-3-fluoropyrrol-3-yl]-N-methylmethanamine monofumarate
Suzuki S et al. *H. pylori* treatment for managing antimicrobial resistance

(TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. *J Pharmacol Exp Ther* 2010; 335: 231-238 [PMID: 20624992 DOI: 10.1124/jpet.110.170274]

26 **Matsukawa J**, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. *Biochem Pharmacol* 2011; 81: 1145-1151 [PMID: 21371447 DOI: 10.1016/j.bcp.2011.02.009]

27 **Sakurai Y**, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, Yoneyama T, Jenkins H, Ashida K, Irie S, Täubel J. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. *Clin Transl Gastroenterol* 2015; 6: e94 [PMID: 26111256 DOI: 10.1038/ctg.2015.18]

28 **Jenkins H**, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. *Aliment Pharmacol Ther* 2015; 41: 636-648 [PMID: 25707624 DOI: 10.1111/apt.13321]

29 **Suzuki S**, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. *Am J Gastroenterol* 2016; 111: 949-956 [PMID: 27185079 DOI: 10.1038/ajg.2016.182]

30 **Murakami K**, Sakurai Y, Shiino M, Funao N, Nishimura A, Akasa M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. *Gut* 2016; 65: 1439-1446 [PMID: 26935876 DOI: 10.1136/gutjnl-2015-311304]

31 **Kusano C**, Gotoda T, Suzuki S, Ikehara H, Moriyama M. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. *J Gastroenterol* 2018; 53: 718-724 [PMID: 29110085 DOI: 10.1007/s00535-017-1406-2]

32 **Furuta T**, Yamada M, Uotani T, Kagi M, Suzuki T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K. *Tul299* - Vonoprazan-Based Dual Therapy with Amoxicillin is as Effective as the Triple Therapy for the Eradication of *H. Pylori*. *Gastroenterology* 2018; 154: S-927 [DOI: 10.1016/S0016-5085(18)33125-1]

33 **Gotoda T**, Takano C, Kusano C, Suzuki S, Ikehara H, Hayakawa S, Andoh A. Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers. *Helicobacter* 2018; 23: e12541 [PMID: 30311721 DOI: 10.1111/hel.12541]

34 **Ierardi E**, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy? *World J Gastroenterol* 2017; 23: 2453-2458 [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453]

35 **Nyssen OP**, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. *Helicobacter* 2019; 24: e12570 [PMID: 30767339 DOI: 10.1111/hel.12570]

36 **Chen MJ**, Chen CC, Chen YN, Chen CC, Fang YJ, Lin JT, Wu MS, Lion JM; Taiwan Gastrointestinal Disease Helicobacter Consortium. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. *Am J Gastroenterol* 2018; 113: 1444-1457 [PMID: 30172126 DOI: 10.1038/s41395-018-0217-2]

37 **Jung YS**, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2017; 46: 106-114 [PMID: 28497487 DOI: 10.1111/ajp.14130]

38 **Lion JM**, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, Lin JT, Chen MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. *Aliment Pharmacol Ther* 2016; 43: 470-481 [PMID: 26669729 DOI: 10.1111/ajp.13495]

39 **Yang X**, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. *Medicine (Baltimore)* 2019; 98: e14396 [PMID: 30762742 DOI: 10.1097/MD.0000000000014396]
